There were more than three dozen court decisions involving life sciences companies in 2019, nine of which related to statements about clinical trial results. Courts dismissed six of these cases at the pleading stage based on the Private Securities Litigation Reform Act of 1995 (PSLRA), while the other three are ongoing.
The stakes associated with defending against litigation past the dismissal stage are high, as evidenced by Hsu v. Puma Biotechnology,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?